Faruqi & Faruqi Investigates Investor Claims Against Aquestive Therapeutics Following Share Price Drop

Investor Alert: Investigation into Aquestive Therapeutics

Faruqi & Faruqi, LLP, a prominent national securities law firm, has initiated an investigation regarding potential claims on behalf of investors in Aquestive Therapeutics, Inc. (NASDAQ: AQST). Following a striking decline in its stock price by nearly 40%, concerns have surfaced after the company reported deficiencies identified by the U.S. Food and Drug Administration (FDA) related to its New Drug Application (NDA) for Anaphylm, its innovative sublingual film designed for treating severe allergic reactions.

On January 17, 2026, the company's disclosure regarding these FDA findings triggered rampant concern among investors, highlighting the uncertainties surrounding Anaphylm’s approval process. The FDA's notification indicated that unresolved deficiencies have stalled progress on discussions regarding product labeling and post-marketing requirements, raising serious doubts about whether the medication will receive approval ahead of the rapidly approaching January 31, 2026 action date for the Prescription Drug User Fee Act (PDUFA).

Investors who have suffered significant losses due to this alarming news are encouraged to seek legal counsel to explore their options. James (Josh) Wilson, a Senior Partner at Faruqi & Faruqi, is directly reaching out to affected investors, inviting them to voice their concerns and discuss potential claims. Interested parties can contact him at 877-247-4292 or through the firm's website.

The implications of the FDA’s report on Aquestive Therapeutics are profound. The firm, which has represented numerous investors since its inception in 1995, emphasizing client confidentiality and a robust track record of recovering significant funds. Faruqi & Faruqi operates in various states, including New York, California, Pennsylvania, and Georgia, embodying a strong national presence in the realm of securities law.

Currently, the primary focus lies on how the deficiencies identified could derail the projected path to market for Anaphylm. Not only does this hinder progress for the company, but it also breeds uncertainty within the investor community regarding the potential viability of their investments.

In light of these developments, investors are advised to remain vigilant. They should assess their positions carefully and consider reaching out to legal experts, particularly those knowledgeable about securities litigation.

In a broader context, transactions involving healthcare products and pharmaceuticals, especially those aimed at treating life-threatening conditions, often face complex regulatory scrutiny. Investors must navigate this convoluted landscape, factoring in the possibility of unforeseen events capable of impacting share prices drastically.

In conclusion, Faruqi & Faruqi's inquiry will seek to uncover the truth regarding the disclosures made by Aquestive Therapeutics and assess whether investors can take legal action for their incurred losses due to the unfavorable developments. The outcome of this investigation may provide critical insights that could affect future decisions of investors involved with the company.

For ongoing updates on this matter, investors are encouraged to follow Faruqi & Faruqi on their social media platforms such as LinkedIn, X, or Facebook to stay informed about this evolving situation and the legal pathways available to them.